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Background: The safety and efﬁcacy of radiofrequency hot balloon catheter (Toray-Satake balloon
[TSB]) ablation for the treatment of atrial ﬁbrillation (AF) was evaluated in a 3-center pilot study.
Methods: Thirty patients (24 men; age, 6178 years) with drug-resistant AF (paroxysmal, n¼24;
persistent, n¼6) were evaluated in this study. The pulmonary veins (PVs) and PV antrum were isolated
using the TSB under general anesthesia (n¼12) or deep sedation (n¼18).
Results: Complete PV isolation was achieved in 110 (92%) of 120 PVs, and decreased PV potentials were
observed in the right superior PV in 4 patients (13%), left superior PV in 4 patients (13%), and left
inferior PV in 2 patients (7%). The mean total procedure time was 104727 min. The mean total
ﬂuoroscopic and total application times were 32714 min and 1272 min, respectively. After a single
session, 22 (73%) and 20 (67%) of the 30 patients were free from AF after 6 and 11.472.2 months of
follow-up, respectively. There were no device-related severe complications such as stroke, esophageal
ﬁstula, symptomatic PV stenosis, phrenic nerve palsy, or pyloric spasm.
Conclusion: TSB catheter ablation might be a promising approach for the treatment of drug-resistant AF.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Pulmonary vein (PV) isolation using a conventional elect-
rode catheter is an effective therapy for atrial ﬁbrillation (AF)
[1,2]. However, it requires a long procedure time and has
occasionally been associated with different complications [3].
Several balloon-based ablation systems have been developed
recently using ultrasound, laser, or cryogenic energy sources
for PV isolation. However, these devices are not efﬁcient for
the ablation of arrhythmogenic foci originating within the PV
antrum [4]. We developed a radiofrequency hot balloon catheter
(Toray-Satake balloon [TSB], Toray Industries, Inc., Tokyo, Japan)
to isolate the PV, PV antrum, and posterior wall of the left
atrium [5]. In this multicenter clinical trial, we evaluated the
safety and efﬁcacy of a radiofrequency hot balloon catheter for
the treatment of AF.rt Rhythm Society. Published by E
a Heart Center, 1898-1
-0116, Japan.
hara).2. Materials and methods
2.1. Patient characteristics
Thirty-two consecutive patients were enrolled in the study, 31 of
whom underwent ablation. One case lacking clinical signiﬁcance was
omitted from the analysis because a malfunction of the RF generator
forced termination of the procedure after only one PV ablation. A total
of 30 patients, including 24 men, with a mean age of 6178 years,
with drug-resistant AF (paroxysmal, n¼24; persistent, n¼6) were
treated in this study (Table 1). Paroxysmal AF was deﬁned as AF that
spontaneously terminated within 7 days. Persistent AF was deﬁned as
AF that was sustained beyond 7 days. The mean left atrial (LA)
diameter was 40.876.0 mm, and the left ventricular ejection fraction
was 66.977.0%. Cardiomyopathy was present in 2 patients, and
hypertension was documented in 14 patients (Table 1). The patients
who underwent open-heart surgery and those who were younger
than 20 years or older than 75 years were excluded.
2.2. Ablation system
The ablation system is composed of a 13F TSB, a 13F deﬂect-
able guiding sheath, and a specially manufactured RF generatorlsevier B.V. All rights reserved.
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20-mm-thick polyurethane balloon membrane is highly elastic
and compliant. The catheter shaft has 2 lm: an inner guide wire
lumen and an outer lumen for transport of the inﬂation ﬂuid and
as a path for the electric cable. The balloon is inﬂated from 26 to
33 mm in diameter, with 10–20 mL of ionized contrast medium
diluted with normal saline (1:1). A coil electrode is mounted on
the shaft within the balloon for the delivery of RF energy, and a
thermocouple is attached to the coil electrode for monitoring the
central balloon temperature. The RF current at 1.8 MHz is deliv-
ered between the coil electrode inside the balloon and the
4 cutaneous electrode patches on the patient’s back to induce
capacitive-type heating of the balloon. A mixing pump works
through the shaft lumen, agitating the inner ﬂuid to maintain
uniform temperature inside the balloon (Fig. 1).
2.3. Electrophysiological study and ablation procedure
Written informed consent was obtained from all the patients.
All antiarrhythmic drugs (AAD) were ceased 5 half-lives before
the procedure. No patients were treated with amiodarone.
The electrophysiological study and ablation procedure wereTable 1




Paroxysmal AF vs. persistent AF 24 vs. 6
Previously ineffective AADs 2.271.2
LAD (mm) by TTE 40.876.0
LVEF (%) by TTE 66.977.0
Follow-up (month) 11.472.2
Cardiomyopathy (%) 2 (6.7)
Hypertension (%) 14 (47)
Fig. 1. Investigational components: radiofrequency hot balloon (TSB) anperformed under deep sedation. Two 5-Fr quadripolar electrode
catheters were placed in the high right atrium and coronary sinus.
The most proximal electrode of the basket catheter (31 mm) was
positioned at the LA-PV junction, as conﬁrmed by the venography
(Figs. 2–5). A surface electrocardiogram and bipolar endocardial
electrograms were continuously recorded and stored on a com-
puter-based digital ampliﬁer/recorder system. Intracardiac elec-
trograms were ﬁltered from 30 to 500 Hz and measured at a
sweep speed of 100–200 mm/s. PV isolation (PVI) was performed
during sinus rhythm except in the patients with persistent AF.
When PVI was performed during AF rhythm, it was conﬁrmed
after the cardioversion.2.4. Balloon ablation
A 13-F steerable guide sheath was inserted into the LA via a
transseptal approach. A deﬂated balloon was inserted through the
guide sheath into the PV ostium with the aid of a guide wire, and
the balloon was inﬂated with ionized ﬂuid.
Optimal positioning of the balloon was determined under the
biplane ﬂuoroscopic view. First, the dilated balloon was wedged
at the PV ostium for PV isolation, and its position was conﬁrmed
by occlusive pulmonary venography after injection of contrast
medium via the inner lumen of the catheter. Second, the antrum
area was ablated by dragging the inﬂated balloon around the PV
ostia (Figs. 2–5). The balloon ablation procedure was initiated by
setting the central temperature of the balloon and the RF energy
delivery time (70 1C3 min for the left superior PV, 68 1C2 min
for the left inferior PV, 70 1C2 min for the right superior PV, and
65 1C2 min for the right inferior PV). These settings were
determined based on previous data [5–7] and according to the
wall thickness measured by intracardiac echocardiography (ICE).
During ablation, 5% glucose was infused at a rate of 30 mL/h,
using an infusion pump during energy delivery to avoid over-
heating of the blood in the PV.d RF generator with mixing system and deﬂectable guiding sheath.
Fig. 2. Location of the balloon and basket catheter during left superior PV (LSPV) isolation. All PV potentials disappeared completely after one procedure. The right panel
shows occlusive venography at the LSPV. All ﬁgures (Figs. 2–5) correspond to the same patient.
Fig. 3. Location of the balloon and basket catheter during left inferior PV (LIPV) isolation. All the PV potentials disappeared completely after one procedure. The right panel
shows occlusive venography at the LIPV.
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Esophageal temperature was monitored with a thermal probe
inserted through a nasogastric tube (Figs. 2 and 3). When the
balloon was close to the esophagus, the esophageal temperature
was monitored during energy delivery. If the temperature
reached 39 1C or higher during ablation, 10–20 mL of cooling
saline was infused through the nasogastric tube into the esopha-
gus. When the esophageal temperature was lowered below 38 1C,
the ablation procedure was continued. When the esophagealtemperature still exceeded 39 1C, the delivery of RF energy was
stopped immediately and the balloon was repositioned to avoid
compression of the esophagus, or the balloon central temperature
was reset down to 65 1C to avoid esophageal damage. After the
procedure, infused saline was aspirated through the nasogastric
tube. During ablation of the right superior PV, the right phrenic
nerve was constantly paced at a rate of 20–30/min, with a bipolar
electrode positioned at the superior vena cava, using a cardiac
stimulator with wide pulse (4–20 ms) and high output (2–40 mA).
Alternatively, ﬂuoroscopy was performed to detect unilateral
Fig. 4. Location of the balloon and basket catheter during right superior PV (RSPV) isolation. Electrical dissociation between the LA and PV is shown after one procedure.
Fig. 5. Location of the balloon and basket catheter during right inferior PV (RIPV) isolation. All the PV potentials disappeared completely after one procedure. The right
panel shows occlusive venography at the RIPV.
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was observed to decrease during ablation, the delivery of RF energy
was stopped and then restarted after repositioning the balloon.
2.6. Procedural end point
The ablation procedure was repeated up to 3 times in each PV
or antrum until the elimination of PV potentials or dissociation
between PV and LA potentials was achieved. Cases in which thePVI was not completed were considered unsuccessful (Table 2)
and additional ablation using a conventional electrode catheter
was not applied to achieve complete PVI.
2.7. Follow-up
The patients were instructed to record an ECG with a mobile
device (Omron, Tokyo, Japan) at a ﬁxed time every week and
when symptoms occurred up to 6 months after ablation. All the
Table 2
Hot balloon ablation procedure data.
Characteristic LSPV LIPV RSPV RIPV
No. of pulmonary veins 30 30 30 30
Diameter (mm) 15.973.1 11.772.7 14.772.7 11.973.2
Max 23.4 19.4 19.6 24.4
Minimum 8.3 8.0 10.6 7.6
Successful pulmonary vein isolation (%) 26 (87) 28 (93) 26 (87) 30 (100)
No. of balloon applications per vein 2.5070.64 2.0370.56 2.6170.62 1.9370.64
Phrenic nerve paralysis (n) 0 0 0 0
Signiﬁcant PV stenosis at follow up (n) 470% 0 0 0 0
PV stenosis at follow up (n) 450% 0 0 1 1
Pyloric spasm (n) 0 0 0 0
Recurrence site at second session (n) Anterior (2) Anterior (2)
Signiﬁcant PV stenosis deﬁned as more than 70% reduction of vessel diameter.
Table 3
Baseline and procedure characteristics of the study patients (n¼30).
PAF (n¼24) P Persistent (n¼6) Total (n¼30) P
Non-recurrence Recurrence Non-recurrence Recurrence Non-recurrence recurrence
Patient no 16 8 4 2 20 10
Age (years) 57.9 (8.5) 64.8 (7.7) 0.07 62.5 (5.8) 64.0 (1.4) 59.6 (8.1) 64.4 (6.9) 0.07b
Sex (male) 13 (81.3%) 5 (62.5%) 0.62 4 (100%) 2 (100%) 17 (85%) 7 (70%) 0.63a
Number of ineffective AADs 2.171.1 2.471.3 0.63 2.871.0 1 2.371.1 2.171.3 0.74b
LAD (mm) by TTE 4.1775.8 38.477.6 0.25 42.473.7 41.070.7 41.875.4 38.976.8 0.21b
LVEF (%) by TTE 67.4 7 7.0 68.975.7 0.6 66.873.9 55.4710.5 67.376.4 66.278.4 0.7b
4PV isolation 13 (87.5%) 5 (55.6%) 0.62 3 (75.0%) 1 (50%) 16 (85.0%) 6 (54.4%) 0.47a
Operation time (min) 93.8724.8 108.6723.9 0.18 113.8740.2 119.0 7 31.1 97.8728.4 110.7723.9 0.23b
Fluoroscopy time (min) 26.8712.1 37.4711.9 0.03 27.5714.6 50.2711.2 26.9712.2 39.9712.4 0.01b
Total ablation time (min) 24.473.5 25.874.7 0.42 23.573.5 28.371.8 24.273.5 26.374.3 0.16b
Ablation number (time) 11.671.5 11.671.5 1.00 13.874.9 1371.4 12.172.5 11.971.5 0.86b
Acute success (%) 92.2 90.6 1.00 93.8 87.5 92.5 90 0.91a
PV number without elimination (%) 10 (15.6) 6 (18.8) 1 (6.3) 1 (12.5) 11 (13.8) 7 (17.5) 0.44a
Values are given as mean7SD or number (percent) unless otherwise indicated.
AADs: antiarrhythmic drugs; LAD: left atrial diameter; LVEF: left ventricular ejection fraction.
a Chi-square analysis.
b Student’s t-test.
H. Sohara et al. / Journal of Arrhythmia 29 (2013) 20–2724patients underwent 3-D CT of the LA and PVs before the
procedure and at 3, 6, and 12 months after ablation to evaluate
the PV stenosis. Signiﬁcant PV stenosis was deﬁned as more than
70% reduction of vessel diameter. The antiarrhythmic drugs were
discontinued when no recurrence of AF was evident after the
8-week blanking period determined in this study. The 48-h Holter
ECG records, which were obtained using a 24-h Holter monitor for
2 consecutive days, were obtained at 6 and 12 months after
ablation. Successful outcome at 6 and 12 months was deﬁned as
the absence of AF (duration430 s) on the 12-lead ECG, 48-h
Holter monitor, and mobile ECG.
2.8. Statistical analysis
Continuous data are presented as means7SD or as a percent
value. Categorical variables were compared between the groups
using the chi-square and Fisher exact probability tests. Contin-
uous variables were compared between the groups by the Student
t-test. All the P values were 2-sided, and Po0.05 was considered
signiﬁcant.3. Results
3.1. Hot balloon ablation procedure data
Of a total of 120 PVs treated with the TSB method, 110 (92%)
were successfully isolated (26 left superior [87%], 28 left inferior[93%], 26 right superior [87%] and 30 right inferior [100%] PVs)
(Table 2). The mean number of balloon applications per vein
was shown in Table 2. No phrenic nerve paralysis, PV stenosis,
or pyloric spasm was observed. Ten patients (PAF: 8, persistent
AF: 2) showed AF recurrence after the blanking period.
No signiﬁcant differences in the parameters examined were
detected between the recurrence and non-recurrence groups
(including PAF and total patients) except the ﬂuoroscopic time
(Table 3).
3.2. Follow-up
All the patients were followed up for 11.472.2 months after
ablation. After a single session, 22 (73%) and 20 (67%) of the
30 patients were free from AF at the 6- and 11.472.2-month
follow-up, respectively (Table 4). During the blanking period,
3 patients (10%) showed early recurrence and required pharma-
cological or electrical cardioversion to restore sinus rhythm. One
of the 10 patients experiencing recurrence 6 months after the
procedure reverted to sinus rhythm without drugs after 12
months.
3.3. Second ablation in recurrence cases
Five of 10 patients with recurrence were remapped after the
blanking period. Only 2 cases showed reconnection between the
LA and PV (LSPV: 2, LIPV: 2), which was located at the anterior
region of the ridge (Fig. 6). The remaining 3 cases had non-PV foci
Table 4
Outcome.






Operation time (min) Fluoroscopy time (min)
A 15 100 87 87 95727 19.773.8
B 6 72 67 67 (83)b 98715 38.479.0
C 9 92 56 33a 122725 47.077.5
Total 30 92 73 67 (70)b 104727 31.6713.9
a Six recurrences include two cases with non-PV foci (posterior LA).
b Including one recurrence case at 6 months after the procedure came back to sinus rhythm without drugs at 12 months.
Fig. 6. Voltage mapping in a case of AF recurrence. The EnSite NavX Velocity System shows that the antral area is widely ablated by the TSB (red color zone is less than
0.03 mV), but the anterior ridge of the LSPV and LIPV (*) show a conduction gap (green and purple). LAO: left anterior oblique. PA: posterior–anterior. RAO: right anterior
oblique.
Fig. 7. Learning curve. A potential learning curve exists for TSB ablation between the ﬁrst procedures performed and more than 7 procedures.
H. Sohara et al. / Journal of Arrhythmia 29 (2013) 20–27 25(posterior LA: 2, SVC: 1) responsible for triggering AF. All the
5 patients underwent conventional ablation procedures and to
date, have been free from AF without drugs.3.4. Complications
Mild stenosis of the PV (450%) after the procedure occurred
in only 2 patients. However, none of the patients showed
signiﬁcant PV stenosis (470%) or severe device-related compli-
cations such as thromboembolic events, phrenic nerve palsy,
pyloric spasm, or esophageal damage during the procedure or
follow-up (Table 2). A pinhole defect in the balloon membrane
occurred in 2 patients due to a procedural failure.3.5. Learning curve
As operators gained experience in the balloon ablation proce-
dure, the ﬂuoroscopic and procedure times became shorter and
the clinical success rate increased (Fig. 7).4. Discussion
4.1. Main ﬁndings
PV isolation using TSB was shown to be a feasible and safe
procedure for the treatment of AF. A total of 110 (92%) of 120 PVs
were successfully isolated by TSB alone, and 20 (67%) of the 30
H. Sohara et al. / Journal of Arrhythmia 29 (2013) 20–2726patients were free from AF without AAD therapy. Furthermore,
the total procedure time was only 104 min, with a short ﬂuoro-
scopic time (31.6 min), and no device-related severe complica-
tions in any of the patients.
4.2. Importance of the proximal antrum area and anterior aspect of
the left PVs
Arrhythmogenic foci located in the posterior LA outside the
antrum and conﬁrmed as triggers for AF were treated by conven-
tional catheter ablation in a second surgical procedure. Isolation
of the posterior wall of the LA is therefore important to obtain
better results even in patients with PAF [8–10]. In fact, RF-based
extensive encircling PVI [11] and box isolation [12] or balloon-
based box isolation [5] were reported to improve clinical out-
come. It is interesting that PV-LA reconnection in the anterior
portion of the left PVs occurred in some of the patients with
AF recurrence. This suggests that the poor contact between the
balloon and the anterior ridge of the left PV caused by the variable
PV anatomy may have resulted in nontransmural ablation with
reconnection. A larger-diameter balloon or balloon ablation com-
bined with conventional catheter ablation (hybrid strategy) might
be useful for achieving durable PVI [13].
4.3. Esophageal damage during balloon-based ablation
A high incidence of asymptomatic esophageal ulceration after
PV isolation by conventional [14] and cryoballoon ablation
procedures [15] has been reported. Singh et al. [16] pointed out
that the esophageal temperature should be kept lower than 41 1C
in conventional ablation to avoid esophageal damage. Chun et al.
also reported that esophageal ulceration could be prevented by
using multiple thermocouples to monitor esophageal tempera-
ture during cryoballoon ablation [17]. In this study, esophageal
injury was prevented by maintaining the esophageal temperature
at lower than 39 1C through the infusion of cooling saline into the
esophagus during hot balloon ablation as previously reported
[5,18]. Therefore, in the next multicenter clinical study, the same
method should be applied to avoid esophageal ulceration.
4.4. Phrenic nerve palsy during balloon-based ablation
Phrenic nerve palsy is a well-known complication of cryobal-
loon ablation, with an incidence rate ranging from 4% to 14%
[19,20]. In some cases, the phrenic nerve palsy continues for
several months despite immediate cessation of the cryogenic
energy application [18]. This was partly due to adhesion of the
frozen balloon to the tissue, which is therefore difﬁcult to with-
draw. On the contrary, the hot balloon does not adhere to the
tissue and can be easily separated as soon as the diaphragmatic
excursion is reduced under phrenic nerve pacing. There were no
cases of phrenic nerve palsy in the present study.
4.5. Previous reports regarding clinical outcome
Calkins et al. [21] described the successful outcomes of radio-
frequency catheter ablation for the treatment of patients with AF
in a meta-analysis. The single procedure success rate of catheter
ablation of AF off AAD therapy was 57% (50–64%) in 31 arms with
2800 patients. After multiple sessions, the off-AAD success rate
increased to 71% (65–77%) in 34 arms with 3481 patients. In the
present study, 20 (67%) of 30 patients were free from AF without
AADs after one ablation session with the TSB procedure, which is
considered a good outcome.4.6. Learning curve
Ruskin et al. reported the effects of the learning curve on the
success of cryoballoon ablation for the treatment of paroxysmal
AF in the STOP AF trial. In their report, the authors observed that
the single-procedure success rate was 70% for surgeons who had
performed 12–23 cryoablations, compared with just 33% for
surgeons who had performed only 1 or 2 procedures. In addition,
experience with the new device allowed doctors to reduce the
total procedure time by 15% and reduce the ﬂuoroscopy time by
24%, compared with ﬁrst-time users. Therefore, increased experi-
ence with the TSB system would improve the clinical outcome of
this procedure (Table 4, Fig. 7).
4.7. Limitations
The present study was limited by the number of patients
included, which was too small to draw conclusions regarding the
efﬁcacy and safety of TSB for the treatment of AF. Furthermore, the
follow-up period was not long enough and the number of enrolled
patients with persistent AF was too small. Another limitation of
this study was the possibility of undetectable asymptomatic AF
recurrence.
However, this is the ﬁrst clinical trial including 3 treatment
centers and midterm follow-up of patients. Larger prospective
controlled trials with longer follow-up periods to evaluate the
feasibility and safety of RF hot balloon catheter (TSB) ablation and
validate our ﬁndings might be required.5. Conclusion
Ablation using a TSB catheter might be a promising approach
for the treatment of drug-resistant AF.Conﬂict of interest
None.
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